

Photo



Application for the following position in the EHRA Board:

President Elect

1. Your Identity

Title: Prof., MD, PhD

Family Name(s): BOVEDA

First Name(s): Serge

Institute / Organisation : Clinique Pasteur Toulouse

Department: Cardiology

Address: BP 27617

Post Code/Zip: 31076

City: Toulouse

Country: France



2. General Curriculum Vitae (300 words max)- Please add your H index and top 10 publications in the last 5 years

- MD, PhD, FESC, FEHRA. Specialist in cardiovascular diseases, interventional treatment of cardiac arrhythmias since 1994.

- Guest Professor at the Brussels University of Medicine (VUB).

- Co-Head of the Cardiac Arrhythmia Management Department, Clinique Pasteur.

- President of the arrhythmia WG of the French Society of Cardiology 2018-2020.

- Co-founder and coordinator of the European Network for the Treatment of Cardiac Arrhythmias (RETAC).

- Secretary of the European Heart Rhythm Association (EHRA) 2024-2026. Chair of the Scientific Program Committee EHRA 2022-2024. Chair of the Scientific Initiative Committee EHRA 2020-2022.

- Faculty of the French national graduation on cardiac arrhythmias (Diplôme Inter Universitaire de Rythmologie, DES option Cardiologie Rythmologie) since 2002.

- Member of the Editorial Board of the Revista Española de Cardiología. Reviewer for Europace, Heart Rhythm, JACC EP, JCE, JICE etc...

- H-index = 58

- 1- Tzeis S, Gerstenfeld EP, Kalman J, Saad EB, Sepehri Shamloo A, Andrade JG, Barbhaiya CR, Baykaner T, **Boveda S**, ..., Trines SA. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. *Europace*. 2024 Mar 30;26(4):euae043. doi: 10.1093/europace/euae043.
- 2- Ferrick AM, Raj SR, Deneke T, Kojodjojo P, Lopez-Cabanillas N, Abe H, **Boveda S**, ..., Varosy PD. 2023 HRS/EHRA/APHS/LAHS Expert Consensus Statement on Practical Management of the Remote Device Clinic. *Europace*. 2023 May 19;25(5):euad123. doi: 10.1093/europace/euad123. PMID: 37208301; PMCID: PMC10199172.
- 3- Kotecha D, Bunting KV, Mehta S, Sommer P, Sterliński M, Rajappan K, Mont L, Guasch E, **Boveda S**, ..., van Gelder IC; STEER-AF investigators. Education of healthcare professionals to improve guideline adherence in atrial fibrillation: the STEER-AF cluster-randomized clinical trial. *Nat Med*. 2025 Aug;31(8):2647-2654. doi: 10.1038/s41591-025-03751-2. Epub 2025 Jun 13. PMID: 40514462; PMCID: PMC12353803.
- 4- Kerkouri F, Eschaliér R, Fareh S, Marquié C, Ait Said M, Amara W, ..., **Boveda S**, Marijon E; HONEST Study Investigators. Defibrillation Testing During Implantation of Subcutaneous Implantable Cardioverter Defibrillators. *J Am Coll Cardiol*. 2025 Jul 8;86(1):32-45. doi: 10.1016/j.jacc.2025.04.048. PMID: 40602942.
- 5- Sousonis V, Jacon P, Kerkouri F, Garcia R, Marquié C, Amara W, ..., **Boveda S**; HONEST Study Investigators. S-ICD Implantation Following TV-ICD: Insights Into Patients With Infections and Abandoned Leads: The HONEST Cohort. *JACC Clin Electrophysiol*. 2025 Sep;11(9):2049-2060. doi: 10.1016/j.jacep.2025.04.020. Epub 2025 Apr 24. PMID: 40358574.
- 6- Chinitz L, **Boveda S**, Richard-Vitton R, Mela T. Applications of leadless pacing. *Eur Heart J Suppl*. 2025 Mar 24;27(Suppl 2):ii8-ii13. doi: 10.1093/eurheartjsupp/suae089. PMID: 40135097; PMCID: PMC11932089.
- 7- **Boveda S**, Sarkozy A, Duncker D, Merino JL. European Heart Rhythm Association congress: a constantly reinvented meeting. *Eur Heart J*. 2024 Aug 21;45(32):2905-2907. doi: 10.1093/eurheartj/ehae327. PMID: 39016166.
- 8- Davong B, Adeliño R, Delasnerie H, Albenque JP, Combes N, Cardin C, ..., **Boveda S**. Pulsed-Field Ablation on Mitral Isthmus in Persistent Atrial Fibrillation: Preliminary Data on Efficacy and Safety. *JACC Clin Electrophysiol*. 2023 Jul;9(7 Pt 2):1070-1081. doi: 10.1016/j.jacep.2023.03.021. Epub 2023 Jun 21. PMID: 37354173.
- 9- Sousonis V, Menè R, Jacob S, Zerrouh S, van Rothen J, Marijon E, ..., **Boveda S**. Temporal Trends in Pacemaker Implantations Over the Past Decade in France: Impact of Transcatheter Aortic Valve Implantations. *Am J Cardiol*. 2023 Sep 15;203:403-405. doi: 10.1016/j.amjcard.2023.07.075. Epub 2023 Jul 29. PMID: 37523936.
- 10- **Boveda S**, Higuera L, Longacre C, Wolff C, Wherry K, Stromberg K, El-Chami MF. Two-year outcomes of leadless vs. transvenous single-chamber ventricular pacemaker in high-risk subgroups. *Europace*. 2023 Mar 30;25(3):1041-1050. doi: 10.1093/europace/euad016. PMID: 36757859; PMCID: PMC10062361.





3. Describe previous experience(s) within EHRA, ESC or your National Cardiac Society

An EHRA member from the very beginning, I have been actively engaged in this remarkable community for over a decade. My service began in 2014 on the Scientific Initiatives Committee, followed by the Scientific Documents Committee as Co-Chair, the Scientific Initiatives Committee in 2020 as Chair, then I became Chair of the Scientific Programme Committee (SPC) in 2022 (organization of EHRA 2023 Barcelona and 2024 Berlin), and I was elected in 2024 to serve as EHRA Secretary.

Across these mandates, I helped design and deliver Europe-wide surveys, including work on leadless devices and patient-reported experiences (e.g., “Living with an ICD”), to inform practice and policy. As SPC Chair, I launched several enduring innovations for the annual congress: the Simulation Village, live-anatomy sessions, and tracings workshops, first introduced at EHRA 2023 in Barcelona and expanded for Berlin 2024 and Vienna 2025.

Like my colleagues, I have given time, energy, and passion. Yet EHRA has given me even more: a broader perspective and the privilege of collaborating with brilliant peers from across Europe, many of whom have become close friends. Nationally, I have been active in the Arrhythmia Working Group of the French Society of Cardiology for more than 25 years, serving repeatedly as an elected member and as President from 2018 to 2020.

If elected President-Elect, I will build on this record of collaboration and innovation to strengthen scientific rigor, elevate education and simulation, and amplify the patient voice across all EHRA activities, together with the President and the Executive Board.





4. Why are you motivated to join the EHRA Executive Board (250 words max)?

I am standing for EHRA President-Elect for the term beginning in 2026, alongside our current President-Elect and future President, Haran Burri, and the Executive Board. My motivation is simple: to facilitate translation of EHRA's expertise into tangible, Europe-wide improvements in education, research, and patient care.

I believe EHRA thrives when we are integrated, pragmatic, and collaborative. As President-Elect, I will focus on three priorities. First, Education: strengthen a competency-based pathway that blends digital learning, high-fidelity simulation, and supervised practice; expand equitable access across countries; and support nurses, allied professionals, and young electrophysiologists with clear certification routes. Second, Research: accelerate multicentre registries and pragmatic trials, promote data interoperability and open science, and broker partnerships with EU programs and industry under clear conflict-of-interest safeguards. Third, Care: turn guidelines into practice through implementation science, quality indicators, and cross-border training networks; reduce unwarranted variation and measure what matters to patients.

I will champion inclusion and transparency in governance, invite broader member participation in agenda-setting if needed, and ensure patient voices are embedded in our work from design to evaluation. I will also prioritize sustainability (financial, operational, and environmental) so our congresses and initiatives remain resilient, accessible, and future-proof.

EHRA has given me a great deal: a community of brilliant colleagues and friends, and a platform to turn ideas into action. I ask for your trust to serve on the Executive Board and to work even harder on this three-pillar mission. With your energy and commitment, we will keep EHRA strong, firmly European, and relentlessly focused on outcomes that matter for patients: safer procedures, better experiences, and longer, healthier lives.





5. How will you combine your EHRA position with your daily clinical/research workload?

Please note that we expect you to:

- Have an active career at the time of taking office
 - Be on clinical practice (for at least 30%) at the time of application
-

After consulting with the current and past EHRA Presidents, and fully aware of the workload, time, and commitment this role of President-Elect requires, I have arranged a 50% part-time appointment at my hospital starting in 2027.

For this reason, and in order to ensure seamless continuity of care and research with my hospital team, I have recruited a talented early-career electrophysiologist to work closely with me. We will operate a structured handover system with defined responsibilities, shared clinic and lab schedules, and regular case reviews. I will retain oversight of complex procedures, ongoing trials, and supervision of fellows, while delegating routine activities to maintain efficiency and safety.

Dedicated administrative support and protected EHRA time are already in place. This model preserves clinical excellence and research momentum in my institution, while giving me the bandwidth to deliver on EHRA priorities with focus, transparency, and accountability.



6. Please list your conflicts of interest

- Direct personal payments (speaker fees, honoraria, advisory board fees, consultancy, investigator...)
 - Industry Employee: 0 %
 - Company (one company): Medtronic
 - Product or therapeutic area: EP
 - ☒ <10 K€/year ☐ 10-50 K€/year ☐ 50-100 K€/year ☐ >100 >K€/year
- Payments to your institution (speaker fees, honoraria, advisory board fees, consultancy, activities executed by your department for the sponsor or investigator initiated and funded by an unconditional grant from the sponsor...)
 - Company (one company): Boston Scientific
 - Product or therapeutic area: EP & CIEDs
 - ☒ <10 K€/ year ☐ 10-50 K€/year ☐ 50-100 K€/year ☐ >100 >K€/year
- Receipts of royalties for intellectual property
 - Company (one company):
 - Product or therapeutic area:
 - ☐ <10 K€/ year ☐ 10-50 K€/year ☐ 50-100 K€/year ☐ >100 >K€/year

Add as many as necessary

Position of influence declaration:

- Direct substantial shareholding or direct financial interest in healthcare, media, education companies or companies in relationship (suppliers or in competition with ESC or in contradiction with ESC mission)
- Employment in healthcare institution (part time or full time)
- Membership or affiliation to political/pressure group associations related to the field of cardiology
- Any potential interest related to the position applied for
- Nothing to declare
- More info at <https://www.escardio.org/The-ESC/About/Policies/esc-declaration-and-management-of-conflict-of-interest-policy>

